Market Place
Sourcing Support
Citius Pharma Reports FDA Meeting on Phase 3 Mino-Lok® Program
25 Nov 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split
22 Nov 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Announces $3 Million Direct Offering
15 Nov 2024 //
PR NEWSWIRE
Citius Pharma Announces Promising Pembrolizumab Trial Results
11 Nov 2024 //
PR NEWSWIRE
Citius Pharmaceuticals` LYMPHIR™ Added to NCCN Guidelines in Oncology
05 Sep 2024 //
PR NEWSWIRE
Citius Pharmaceuticals to Join H.C. Wainwright Global Investment Conference
05 Sep 2024 //
PR NEWSWIRE
Citius Pharmaceuticals To Host Investor Call On Recent Developments
12 Aug 2024 //
PR NEWSWIRE
Citius Completes Merger To Form Citius Oncology, Inc.
12 Aug 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Reports Q3 2024 Results And Business Update
12 Aug 2024 //
PR NEWSWIRE
US FDA approves Citius` therapy for rare blood cancer
09 Aug 2024 //
REUTERS
Citius Pharma Announces Shareholder Approval Of Oncology Merger
05 Aug 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
10 Jul 2024 //
PR NEWSWIRE
Citius To Host Call On Mino-Lok Phase 3 Topline Results
30 May 2024 //
PR NEWSWIRE
Citius Achieves Mino-Lok Phase 3 Primary, Secondary Endpoints
21 May 2024 //
PR NEWSWIRE
Citius Pharma Reports Fiscal Q2 2024 Results, Business Update
14 May 2024 //
PR NEWSWIRE
Citius At Upcoming EF Hutton, HC Wainwright Conferences
10 May 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
26 Apr 2024 //
PR NEWSWIRE
Citius Adds City Of Hope To UMN LYMPHIR + CAR-T Trial
11 Apr 2024 //
PR NEWSWIRE
Citius Pharma to Present at the LD Micro Invitational XIV Investor Conference
04 Apr 2024 //
PR NEWSWIRE
Citius Announces FDA Acceptance of the BLA Resubmission of LYMPHIR for CTCL
18 Mar 2024 //
PR NEWSWIRE
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Program
07 Mar 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement
26 Feb 2024 //
PR NEWSWIRE
Citius to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
23 Feb 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR
14 Feb 2024 //
PR NEWSWIRE
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results
14 Feb 2024 //
PR NEWSWIRE
Citius Announces Nomination of Executive Robert J. Smith to Board of Directors
23 Jan 2024 //
PR NEWSWIRE
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results
02 Jan 2024 //
PR NEWSWIRE
Citius Completes Enrollment in Phase 3 Trial of Mino-Lok to Salvage Catheters
02 Jan 2024 //
PR NEWSWIRE
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference
09 Nov 2023 //
PR NEWSWIRE
Citius Announces Publication of Positive Results from Tumor Study of LYMPHIR
31 Oct 2023 //
PR NEWSWIRE
Citius Pharmaceuticals Executes Definitive Agreement to Merge with TenX Keane
24 Oct 2023 //
PR NEWSWIRE
Citius Reschedules Participation in Sidoti Small-Cap Investor Conference
18 Sep 2023 //
PR NEWSWIRE
Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir
13 Sep 2023 //
PR NEWSWIRE
Citius Pharmaceuticals looks to refile former Eisai cancer drug in early 2024
08 Sep 2023 //
ENDPTS
Citius Receives Regulatory Guidance from FDA regarding BLA for LYMPHIR
08 Sep 2023 //
PR NEWSWIRE
Citius to Participate in H.C. Wainwright and Sidoti Investor Conferences
06 Sep 2023 //
PR NEWSWIRE
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results
14 Aug 2023 //
PR NEWSWIRE
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial
10 Aug 2023 //
PR NEWSWIRE
FDA asks Citius for enhanced product testing in CRL for drug Lymphir
31 Jul 2023 //
ENDPTS
Citius` $40M gamble to revive Eisai`s Ontak hits wall at FDA
31 Jul 2023 //
FIERCE PHARMA
Citius Pharmaceuticals Receives a CRL from the U.S. FDA (FDA) for LYMPHIR™
29 Jul 2023 //
PR NEWSWIRE
Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes
26 Jun 2023 //
PR NEWSWIRE
Citius Pharmaceuticals files patent for Halo-Lido after Phase IIb trial
21 Jun 2023 //
CLINICAL TRIALS ARENA
Citius Pharma Announces +ve Results from the Phase 2b Study
20 Jun 2023 //
PR NEWSWIRE
Citius to Participate in Maxim Group`s Healthcare Conference on June 21, 2023
13 Jun 2023 //
PR NEWSWIRE
Citius Pharmaceuticals Reports Fiscal 2Q 2023 FYR and Provides Business Update
12 May 2023 //
PR NEWSWIRE
Citius Pharmaceuticals Announces Closing of $15 M Registered Direct Offering
08 May 2023 //
PR NEWSWIRE
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
04 May 2023 //
PR NEWSWIRE
Citius Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date
24 Apr 2023 //
PR NEWSWIRE
Citius Completes Enrollment in Phase 2b Study of Halo-Lido
03 Apr 2023 //
PR NEWSWIRE
Citius Advances Efforts to Spin Off Oncology Asset
30 Mar 2023 //
PR NEWSWIRE
Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank
13 Mar 2023 //
PR NEWSWIRE
Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference
08 Mar 2023 //
PR NEWSWIRE
Citius Reports Fiscal First Quarter 2023 Financial Results
10 Feb 2023 //
PR NEWSWIRE
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference
11 Jan 2023 //
PR NEWSWIRE
Citius Pharma Reports Fiscal Full Year 2022 FY & Provides Business Update
22 Dec 2022 //
PRNEWSWIRE
Citius Pharma Announces U.S. FDA Acceptance of BLA of Denileukin Diftitox
01 Dec 2022 //
PRNEWSWIRE
Citius Secures $3.6 million through New Jersey Economic Development Program
21 Nov 2022 //
PRNEWSWIRE
Citius Pharmaceuticals Announces Efficacy & Safety Data for its I/ONTAK (E7777)
09 Nov 2022 //
PRNEWSWIRE
Citius to Present at Dawson James Securities Small Cap Growth Conference
06 Oct 2022 //
PRNEWSWIRE
